Androgen-modulated p21 and p53 gene expression in human non-transformed epithelial prostatic cells in primary cultures

International Journal of Molecular Medicine

Volumn 30, Issue 4, 2012, Pages 967-973

  Pozzobon, Adriane ^a   Schneider, L ^b   Brum, I S ^b  

^a Center for Health Sciences   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Androgen; p21; p53; Proliferation; Prostate

Indexed keywords

ANDROSTANOLONE; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL GROWTH; CLINICAL ARTICLE; DOSE RESPONSE; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

AGED; ANDROGENS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIHYDROTESTOSTERONE; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866524966     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1082     Document Type: Article

References (54)

1. Sonnenschein C, Olea N, Pasanen ME and Soto AM: Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res 49: 3474-3781, 1989.
2. Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ and Brodie AM: Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60: 6630-6640, 2000.
3. Haynes JM, Frydenberg M and Majewski H: Testosterone- and phorbol ester-stimulated proliferation in human cultured prostatic stromal cells. Cell Signal 13: 703-709, 2001.
4. Culig Z, Hobisch A, Bartsch G and Klocker H: Androgen receptor - an update of mechanisms of action in prostate cancer. Urol Res 28: 211-219, 2000.
5. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD and Sun Z: A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res 35: 2767-2776, 2007.
6. Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML and Balk SP: Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169: 682-696, 2006.
7. Blanchere M, Berthaut I, Portois MC, Mestayer C and Mowszowicz I: Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J Steroid Biochem Mol Biol 66: 319-326, 1998.
8. Avances C, Georget V, Terouanne B, Orio F, Cussenot O, Mottet N, Costa P and Sultan C: Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens. Mol Cell Endocrinol 184: 13-24, 2001.
9. Planz B, Wang Q, Kirley SD, Marberger M and McDougal WS: Regulation of keratinocyte growth factor receptor and androgen receptor in epithelial cells of the human prostate. J Urol 166: 678-683, 2001.
10. Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan WL and Yamanaka H: Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J 46: 405-413, 1999.
11. Arnold JT, Liu X, Allen JD, Le H, McFann KK and Blackman MR: Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 67: 1152-1162, 2007.
12. Berthon P, Waller AS, Villette JM, Loridon L, Cussenot O and Maitland NJ: Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. Int J Cancer 73: 910-916, 1997.
13. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP and Brown TJ: Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 126: 59-73, 1997.
14. Krill D, Stoner J, Konety BR, Becich MJ and Getzenberg RH: Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology 54: 171-177, 1999.
15. Joly-Pharaboz MO, Soave MC, Nicolas B, Mebarki F, Renaud M, Foury O, Morel Y and Andre JG: Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 55: 67-76, 1995.
16. Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, Andre J, Chantepie J, Nicolas B and Panaye G: Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 73: 237-249, 2000.
17. Shao C, Wang Y, Yue HH, Zhang YT, Shi CH, Liu F, Bao TY, Yang ZY, Yuan JL and Shao GX: Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. J Androl 28: 804-812, 2007.
18. Geck P, Szelei J, Jimenez J, Lin TM, Sonnenschein C and Soto A: Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells. J Steroid Biochem Mol Biol 63: 211-218, 1997.
19. Silva IS, Morsch DM, Urnauer L and Spritzer PM: Androgen-induced cell growth and c-myc expression in human non-transformed epithelial prostatic cells in primary culture. Endocr Res 27: 153-169, 2001.
20. Brum IS, Morsch DM, Pozzobon A, Boeri VA, Geib G and Spritzer PM: Androgen-dependent expression of c-jun and c-fos in human non-transformed epithelial prostatic cells: association with cell proliferation. Hormone Res 60: 209-214, 2003.
21. Buttyan R, Shabsigh A, Perlman H and Colombel M: Regulation of apoptosis in the prostate gland by androgenic steroids. Trends Endocrinol Metab 10: 47-54, 1999.
22. Solomon MJ and Kaldis P: Regulation of CDKs by phosphorylation. Results Probl Cell Differ 22: 79-109, 1998.
23. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
24. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
25. Robson CN, Gnanapragasam V, Byrne RL, Collins AT and Neal DE: Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol 160: 257-266, 1999.
26. Lu S, Tsai SY and Tsai MJ: Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 140: 5054-5059, 1999.
27. Ling MT, Chan KW and Choo CK: Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 170: 287-296, 2001.
28. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-944, 1995.
29. Downing S, Jackson P and Russell P: Mutations within the tumor suppressor gene p53 are not confined to a late event in prostate cancer progression: a review of the evidence. Urol Oncol 6: 103-110, 2001.
30. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE and Cohen MB: Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24: 6773-6784, 2005.
31. Wang LG, Ossowski L and Ferrari AC: Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 61: 7544-7551, 2001.
32. Spritzer PM, Silva IS, Oliveira IO, Morsch DM and Coral G: Culture of adult human prostatic epithelial cells: A simplified method for obtaining primary cultures. Med Sci Res 23: 379-381, 1995.
33. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
34. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN and Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398, 1995.
35. Bradford M: A rapid and sensitive method for quantitation of microgram quanties of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-255, 1976.
36. Olea N, Sakabe K, Soto AM and Sonnenschein C: The proliferative effect of 'anti-androgens' on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126: 1457-1463, 1990.
37. He B, Chen J, Basrawala Z, Xin H and Choubey D: The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 277: 10226-10235, 2002.
38. Chan TO, Rittenhouse SE and Tsichlis PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 68: 965-1014, 1999.
39. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS and Cohen MB: p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 19: 1959-1968, 2000.
40. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C and McDonnell TJ: Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 169: 1553-1557, 2003.
41. Nantermet PV, Xu J, Yu Y, Hodor P, Holder D, Adamski S, Gentile MA, Kimmel DB, Harada S, Gerhold D, et al: Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem 279: 1310-1322, 2004.
42. Khan OY, Fu G, Ismail A, Srinivasan S, Cao X, Tu Y, Lu S and Nawaz Z: Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol Endocrinol 20: 544-559, 2006.
43. Zhou JR, Yu L, Zerbini LF, Libermann TA and Blackburn GL: Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 110: 800-806, 2004.
44. Schwarze SR, Shi Y, Fu VX, Watson PA and Jarrard DF: Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20: 8184-8192, 2001.
45. Li R, Waga S, Hannon GJ, Beach D and Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371: 534-537, 1994.
46. Lu S, Jenster G and Epner DE: Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14: 753-760, 2000.
47. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY and Chang C: Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci USA 97: 11256-11261, 2000.
48. Lu S, Liu M, Epner DE, Tsai SY and Tsai MJ: Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13: 376-384, 1999.
49. Alimirah F, Chen J, Basrawala Z, Xin H and Choubey D: DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett 580: 2294-2300, 2006.
50. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA and Chaudhary J: Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer 9: 173, 2009.
51. McConnell JD: Prostatic growth: new insights into hormonal regulation. Br J Urol 76: 5-10, 1995.
52. Gotoh A, Shirakawa T, Wada Y, Fujisawa M, Okada H, Kamidono S and Hamada K: The growth inhibitory effect of p21 adenovirus on androgen-dependent and -independent human prostate cancer cells. BJU Int 92: 314-318, 2003.
53. Miyake H, Tolcher A and Gleave ME: Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 59: 4030-4034, 1999.
54. Concato J, Jain D, Uchio E, Risch H, Li WW and Wells CK: Molecular markers and death from prostate cancer. Ann Intern Med 150: 595-603, 2009.